Publication

Xultophy : combination therapy for the treatment of type 2 diabetes

Chaplin, Steve
; 
Abstract
Xultophy is the first product to combine a basal insulin and an incretin mimetic for the treatment of type 2 diabetes. Here Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Vinod Patel outlines its place in therapy.
MIDER Authors
Patel, Vinod
Affiliations
George Eliot Hospital NHS Trust, Nuneaton
Citations
Altmetric:
Date
2015-09-04
Type
Article
Subject
Diabetes
 Pharmacology
Collections
GEH Diabetes and Endocrinology
Show all metadata
Citation
Chaplin S, Patel V. Xultophy: Combination therapy for the treatment of type 2 diabetes. Prescriber. 2015 September;26(17):32-34. doi: 10.1002/psb.1382.
Journal / Source Title
Prescriber
DOI
10.1002/psb.1382
URI
http://hdl.handle.net/20.500.14200/7361
PMID
Publisher
Wiley
Publisher’s URL
Publisher’s statement
Note / Copyright